RT Journal Article
SR Electronic
T1 Genomically informed clinical comparison of three epidemic waves of COVID-19 in Malawi
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.02.17.22269742
DO 10.1101/2022.02.17.22269742
A1 Anscombe, Catherine
A1 Lissauer, Samantha
A1 Thole, Herbert
A1 Rylance, Jamie
A1 Dula, Dingase
A1 Menyere, Mavis
A1 Kutambe, Belson
A1 van der Veer, Charlotte
A1 Phiri, Tamara
A1 Banda, Ndaziona P.
A1 Mndolo, Kwazizira S.
A1 Mponda, Kelvin
A1 Phiri, Chimota
A1 Mallewa, Jane
A1 Nyirenda, Mulinda
A1 Katha, Grace
A1 Mwandumba, Henry
A1 Gordon, Stephen B.
A1 Jambo, Kondwani C.
A1 Cornick, Jennifer
A1 Feasey, Nicholas
A1 Blantyre COVID-19 Consortium
A1 Barnes, Kayla G.
A1 Morton, Ben
A1 Ashton, Philip M.
YR 2022
UL http://medrxiv.org/content/early/2022/02/19/2022.02.17.22269742.abstract
AB Background Compared to the abundance of clinical, molecular, and genomic information available on patients hospitalised with COVID-19 disease from high-income countries, there is a paucity of data from low-income countries.Methods We enrolled 245 hospitalised patients with PCR confirmed COVID-19 disease at Queen Elizabeth Central Hospital, the main hospital for southern Malawi, between July 2020 and September 2021. The recruitment period covered three waves of SARS-CoV-2 infections in Malawi. Clinical and diagnostic data were collected using the ISARIC clinical characterization protocol for COVID-19. The viral material from PCR-positive swabs was amplified with a tiling PCR scheme and sequenced using the MinION sequencer in Malawi. Consensus genomes were generated using the ARTIC pipeline and lineage assignment was performed using Pangolin.Results Sequencing data showed that wave one was predominantly B.1 (8/11 samples), wave two consisted entirely of Beta variant of concern (VOC) (6/6), and wave three was predominantly Delta VOC (25/26). Patients recruited during the second and third waves had progressively fewer underlying chronic conditions, and in the third wave had a shorter time to presentation (2 days vs 5 in the original wave). Multivariable logistic regression demonstrated increased mortality in wave three, dominated by the Delta VOC, compared to previous waves (OR 6.6 [CI 1.1-38.8]).Conclusions Patients hospitalised with COVID-19 disease and who were recruited to the ISARIC cohort, in Blantyre during the Delta wave had more acute symptom onset; fewer underlying conditions; and were more likely to die. Whilst we demonstrate the value of linking virus sequence data with clinical outcome data in a low-income setting, this study also highlights the considerable barriers to establishing sequencing capacity in a setting heavily affected by disruptions in supply chain and inequity of resource distribution.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by the UK Foreign, Commonwealth and Development Office and Wellcome [220757/Z/20/Z].Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Study protocols were approved by the Malawi National Health Science Research Committee (NHSRC, 20/02/2518 and 19/08/2246) and Liverpool School of Tropical Medicine Research Ethics Committee (LSTM REC, 20/026 and 19/017).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll genome sequences are available in GISAID. Accessions are available in Supplementary Table 2.